Actively Recruiting
A Clinical Trial of CEA Targeting CAR-T for CEA Positive Advanced Lung Cancer
Led by Chongqing Precision Biotech Co., Ltd · Updated on 2025-01-10
48
Participants Needed
1
Research Sites
159 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Lung cancer is the leading cause of morbidity and mortality in the world, of which 80%-85% are non-small cell lung cancer (NSCLC). Most patients with NSCLC are at the advanced stage of diagnosis and have a poor prognosis. The 5-year survival rate of stage III patients is about 15%, the 5-year survival rate of stage IV patients is less than 5%, and the median survival time is only 7 months. CEACAM5 (CEA), also known as CD66e, is a classic tumor marker that has been used as a marker for many types of tumors for 50 years. It is mainly expressed in lung cancer, esophageal cancer, bile duct cancer, colorectal cancer, gastric cancer and other tumor types. In previous CAR-T-related clinical trials targeting CEA, the research team found that CAR-T cell preparations had a certain killing effect on CEA positive tumor cells. At the same time, CAR-T cell preparations cannot be sustained for a long time in the body, which is also a key factor restricting the anti-tumor effect of CAR-T cells in the body. To solve this problem, the killing ability and survival ability of CAR-T cell preparations on tumor cells in vitro and in vivo were improved by optimizing CAR structure and improving culture mode.
CONDITIONS
Official Title
A Clinical Trial of CEA Targeting CAR-T for CEA Positive Advanced Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older, any gender
- Histologically or pathologically confirmed advanced, metastatic, or recurrent lung cancer, including non-small cell and small cell lung cancer
- Disease progression or intolerance to at least second-line standard therapy; patients with driver gene positive NSCLC must have had targeted therapy, others must have had platinum-containing chemotherapy
- Tumor samples within 3 months showing CEA positivity with at least 10% positive rate; if older than 3 months, serum CEA must exceed 10 ug/L
- At least one measurable lesion per RECIST 1.1, extranodal lesion length at least 10 mm, or lymph node short diameter at least 15 mm
- ECOG performance status score between 0 and 2
- Expected survival time over 12 weeks
- No serious mental disorders
- Satisfactory vital organ function including neutrophils >1.0x10^9/L, platelets >75x10^9/L, hemoglobin >80 g/L, cardiac ejection fraction ≥50%, serum creatinine ≤2.0 times upper limit of normal, ALT and AST ≤3.0 times upper limit (or ≤5.0 with liver tumor infiltration), total bilirubin ≤2.0 times upper limit, and blood oxygen saturation >92% without oxygen
- Eligible for simple or intravenous blood collection without contraindications
- Agree to use reliable contraception for 1 year from consent to CAR T cell infusion
- Provide informed consent and agree to participate in the study
You will not qualify if you...
- Central nervous system metastasis or meningeal metastasis with clinical symptoms or uncontrolled status
- Participation in other clinical trials within 1 month before screening
- Receipt of live attenuated vaccine within 4 weeks before screening
- Anti-tumor therapies such as chemotherapy, targeted therapy, or investigational agents within 14 days or 5 half-lives before screening
- Active or uncontrolled infections requiring systemic treatment
- Tumor compressing trachea or major blood vessels with high risk as assessed by researchers
- Large uncontrollable fluid accumulation in serous cavities
- Toxicity from prior anti-tumor therapy not improved to baseline or grade ≤1 (except alopecia or peripheral neuropathy)
- Severe heart conditions including NYHA Class III/IV heart failure, recent myocardial infarction or coronary artery bypass within 6 months, significant ventricular arrhythmias, unexplained syncope, or severe non-ischemic cardiomyopathy
- Active autoimmune diseases or need for long-term immunosuppression
- Other untreated malignant tumors within past 3 years except certain skin and cervical cancers
- Positive hepatitis B, hepatitis C, HIV, or syphilis tests with abnormal viral levels
- Pregnant or breastfeeding women
- Other conditions deemed unsuitable by investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Actively Recruiting
Research Team
C
Chu Qian, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here